Posts Tagged ‘cell and gene therapies’

Reimbursement – the final frontier

Author: Guest, 07/06/17

Patrick Bedford is the Senior Manager of Clinical Translation and Regulatory Affairs at CCRM. He holds a Master’s Degree in Bioethics and Health Law, and a Regulatory Affairs Certificate. Patrick has spent over 11 years applying federal regulations to emerging biotechnologies in Canada. Follow him on LinkedIN. Although I’m officially CCRM’s “regulatory guy,” I’ve been talking a…Read more

Right Turn: Synthetic biology predicted to become a huge industry

Author: Stacey Johnson, 02/10/17

There is a trend in the regenerative medicine field to include gene therapies when describing the work being performed by academics and industry, as in “cell and gene therapies.” The wider definition better reflects how the industry is evolving and acknowledges the dual focus. I expect the same may happen with synthetic biology’s role in…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

ISCT webinar: Reimbursement re-cap

Author: Mark Curtis, 12/28/15

For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on the ISCT website shortly. Thanks again to ISCT for hosting and Invetech, a member of…Read more